{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:10:37Z","timestamp":1787760637887,"version":"build-2784847793"},"reference-count":249,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Secondary antibody deficiencies (SADs) are characterized by impaired humoral immunity, which can cause recurrent and severe infections. Several factors may contribute to SAD development, making it difficult to establish a clear etiological classification. This heterogeneity also leads to clinical variability, further complicating patient management and treatment strategies. Various diagnostic and therapeutic algorithms are often adapted from those used in primary antibody deficiencies, potentially resulting in under- or over-treatment. Key points include the decision to initiate Immunoglobulin Replacement Therapy (IgRT) and the duration of the treatment. Given the increasing prevalence of SADs and the limited availability of immunoglobulin products, it is important to clarify when IgRT should be started. In this review, we summarize and update the different etiologies of SADs and propose a diagnostic algorithm applicable regardless of the underlying cause. We also examine the possible treatment options and diagnostic tools that can assist in making the correct therapeutic choice.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1672413","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:33:28Z","timestamp":1764830008000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Secondary antibody deficiencies: what\u2019s around the corner?"],"prefix":"10.3389","volume":"16","author":[{"given":"Gianluca","family":"Lagnese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Messuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Poto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Varricchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000215","article-title":"Secondary antibody deficiencies","volume":"15","author":"Dhalla","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.902314","article-title":"Secondary antibody deficiency","volume":"10","author":"Duraisingham","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: Causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.08.040","article-title":"Secondary immunodeficiencies, including HIV infection","volume":"125","author":"Chinen","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.09.005","article-title":"Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach","volume":"52","author":"Pecoraro","year":"2017","journal-title":"Int Immunopharmacology."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin Exp Immunol Blackwell Publishing Ltd;"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2008.07.002","article-title":"Preparation and use of therapeutic antibodies primarily of human origin","volume":"36","author":"Stiehm","year":"2008","journal-title":"Biologicals."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9511-0","article-title":"Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study","volume":"31","author":"Quinti","year":"2011","journal-title":"J Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1788939","article-title":"Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency","volume":"16","author":"Patel","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2176843","article-title":"Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review","volume":"16","author":"Cinetto","year":"2023","journal-title":"Expert Rev Hematology."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000696","article-title":"Global immunoglobulin supply: steaming towards the iceberg","volume":"20","author":"Prevot","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B12","volume-title":"Guidelines on the use of human immunoglobulins in case of shortages","author":"Di Giorgio","year":"2022"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29438","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.18502\/ijhoscr.v16i1.8437","article-title":"ijhoscr.tums.ac.ir","volume":"16","author":"Yokus","year":"2022","journal-title":"Int J Hematology-Oncology Stem Cell Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.05.008","article-title":"Recommendations for management of secondary antibody deficiency in multiple myeloma","volume":"23","author":"Giralt","year":"2023","journal-title":"Clin Lymphoma Myeloma Leukemia."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24245","article-title":"Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma","volume":"124","author":"Biggar","year":"2009","journal-title":"Int J Cancer."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00062-5","article-title":"Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial","volume":"10","author":"Alexander","year":"2023","journal-title":"Lancet Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1380654","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patient","volume":"15","author":"Elgenidy","year":"2024","journal-title":"Front Neurology."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127247","article-title":"Hypogammaglobulinemia and its implications in patients treated with daratumumab: A single institution experience","volume":"134","author":"Paul","year":"2019","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"AB231","DOI":"10.1016\/j.jaci.2023.11.741","article-title":"Hypogammaglobulinemia and risk of infection following daratumumab in patients with multiple myeloma","volume":"153","author":"Hong","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.575168","article-title":"Real world experience of daratumumab: evaluating lymphopenia and adverse events in multiple myeloma patients","volume":"10","author":"Cottini","year":"2021","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunology: In Practice."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.76","article-title":"Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT","volume":"48","author":"Frangoul","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0264-7","article-title":"Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency","volume":"36","author":"Wirsum","year":"2016","journal-title":"J Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e3283186bbc","article-title":"Hypogammaglobulinemia and infection risk in solid organ transplant recipients","volume":"13","author":"Mawhorter","year":"2008","journal-title":"Curr Opin Organ Transplantation."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/gou082","article-title":"Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease","volume":"3","author":"Rai","year":"2015","journal-title":"Gastroenterol Rep (Oxf)."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314525248","article-title":"Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil","volume":"23","author":"Yap","year":"2014","journal-title":"Lupus."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000533699","article-title":"Associations between antiepileptic use and hypogammaglobulinaemia: findings from a population-based case-control study using data linkage","volume":"57","author":"Perrott","year":"2023","journal-title":"Neuroepidemiology."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2018.152","article-title":"Clozapine is associated with secondary antibody deficiency","volume":"214","author":"Ponsford","year":"2019","journal-title":"Br J Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.04.061","article-title":"Immune abnormalities in fontan protein-losing enteropathy: A case-control study","volume":"167","author":"Magdo","year":"2015","journal-title":"J Pediatrics."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05652-9","article-title":"The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome","volume":"38","author":"Inoki","year":"2023","journal-title":"Pediatr Nephrology."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-021-05304-4","article-title":"Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome","volume":"37","author":"Inoki","year":"2022","journal-title":"Pediatr Nephrology."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2014.06.025","article-title":"Relationship between hypogammaglobulinemia and severity of atopic dermatitis","volume":"113","author":"Celiksoy","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105017","article-title":"The immune system in children with malnutrition - A systematic review","volume":"9","author":"Rytter","year":"2014","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2375","article-title":"Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection","volume":"103","author":"De Milito","year":"2004","journal-title":"Blood."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1098326","article-title":"Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review","volume":"13","author":"Jolles","year":"2023","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738915","article-title":"Secondary immunodeficiency in hematological Malignancies: focus on multiple myeloma and chronic lymphocytic leukemia","volume":"12","author":"Allegra","year":"2021","journal-title":"Front Immunol"},{"key":"B40","unstructured":"Tsai\n              HT\n            \n            \n              Caporaso\n              NE\n            \n            \n              Kyle\n              RA\n            \n            \n              Katzmann\n              JA\n            \n            \n              Dispenzieri\n              A\n            \n            \n              Hayes\n              RB\n            \n          \n          Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study"},{"key":"B41","volume-title":"Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction","author":"Sampalo","year":"2000"},{"key":"B42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","article-title":"Immune defects in patients with chronic lymphocytic leukemia","volume":"55","author":"Ravandi","year":"2006","journal-title":"Cancer Immunology Immunother"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594556","article-title":"Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia","volume":"11","author":"Griggio","year":"2020","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/ajh.2830190109","article-title":"Defective complement activity in chronic lymphocytic leukemia","volume":"19","author":"Heath","year":"1985","journal-title":"Am J Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1992.tb06965.x","article-title":"Predictors of infection in chronic lymphocytic leukaemia (CLL)","volume":"89","author":"Griffiths","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/10428194.2012.706285","article-title":"Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia","volume":"54","author":"Freeman","year":"2013","journal-title":"Leuk Lymphoma."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062376","article-title":"Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia","volume":"14","author":"Noto","year":"2023","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092278","article-title":"Clinical considerations for immunoparesis in multiple myeloma","volume":"14","author":"Chahin","year":"2022","journal-title":"Cancers."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0163-4","article-title":"Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials","volume":"32","author":"Heaney","year":"2018","journal-title":"Leukemia."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Vol. 138 Br J Haematology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1002\/ajh.26752","article-title":"The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception","volume":"98","author":"Dhodapkar","year":"2023","journal-title":"Am J Hematology. John Wiley Sons Inc;"},{"key":"B53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00277-017-3191-7","article-title":"Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate","volume":"97","author":"Leleu","year":"2018","journal-title":"Ann Hematol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.jaci.2015.10.018","article-title":"IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration","volume":"137","author":"Kulkarni","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1954","article-title":"Plasma cells negatively regulate the follicular helper T cell program","volume":"11","author":"Pelletier","year":"2010","journal-title":"Nat Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev-immunol-020711-075027","article-title":"Pathogenesis of human B cell lymphomas","volume":"30","author":"Shaffer","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":":110332","DOI":"10.1016\/j.clim.2024.110332","article-title":"Pediatric lymphoproliferative disorders associated with inborn errors of immunity","volume":"266","author":"Cheng","year":"2024","journal-title":"Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1334899","article-title":"Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis","volume":"15","author":"Brazel","year":"2024","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70014","article-title":"Hypogammaglobulinemia at diagnosis is associated with inferior survival and higher risk of infections in diffuse large B cell lymphoma","volume":"43","author":"Lindberg","year":"2025","journal-title":"Hematol Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.10.013","article-title":"Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study","volume":"39","author":"De Angelis","year":"2015","journal-title":"Leuk Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of Rituximab-The world\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: Final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"Van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7010305","article-title":"Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: What do we know and what can we learn from adults","volume":"7","author":"Worch","year":"2015","journal-title":"Cancers"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2010058","article-title":"The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma","volume":"63","author":"Fischer","year":"2022","journal-title":"Leuk Lymphoma."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vaccines Immunotherapeutics."},{"key":"B68","doi-asserted-by":"crossref","first-page":"106191","DOI":"10.1016\/j.msard.2024.106191","article-title":"Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: A multicentre study","volume":"93","author":"Smolik","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Multiple Sclerosis Related Disord"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J Neuroimmunol."},{"key":"B71","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am J Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12948-019-0113-3","article-title":"Immunosuppressive therapy with rituximab in common variable immunodeficiency","volume":"17","author":"Pecoraro","year":"2019","journal-title":"Clin Mol Allergy"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"New Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"New Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton\u2019s tyrosine kinase: From X-linked agammaglobulinemia toward targeted therapy for B-cell Malignancies","volume":"32","author":"Ponader","year":"2014","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1772477","article-title":"Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors","volume":"61","author":"Pleyer","year":"2020","journal-title":"Leuk Lymphoma."},{"key":"B77","unstructured":"Sun\n              C\n            \n            \n              Tian\n              X\n            \n            \n              Lee\n              YS\n            \n            \n              Gunti\n              S\n            \n            \n              Lipsky\n              A\n            \n            \n              Herman\n              SEM\n            \n          \n          Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib Key Points"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Diseases."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1602268","article-title":"Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice","volume":"60","author":"Hampel","year":"2019","journal-title":"Leuk Lymphoma."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121527","article-title":"Cd38, a receptor with multifunctional activities: From modulatory functions on regulatory cell subsets and extracellular vesicles, to a target for therapeutic strategies","volume":"8","author":"Morandi","year":"2019","journal-title":"Cells."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"B82","unstructured":"Highlights of prescribing information"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003604","article-title":"Daratumumab for autoimmune diseases: A systematic review","volume":"9","author":"Holzer","year":"2023","journal-title":"RMD Open"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/antib8030043","article-title":"Design and production of bispecific antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies"},{"key":"B85","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Vol. 67 Mol Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer. John"},{"key":"B87","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"New Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.789509","article-title":"Acute lymphoblastic leukemia in adults: Encouraging developments on the way to higher cure rates","volume":"54","author":"Mathisen","year":"2013","journal-title":"Leukemia Lymphoma."},{"key":"B90","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/bcj.2014.64","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier","year":"2014","journal-title":"Blood Cancer J"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.5045\/br.2022.2021163","article-title":"Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk","volume":"57","author":"Wo","year":"2022","journal-title":"Blood Res"},{"key":"B92","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Policy Rev Lancet Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"B94","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"New Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010094","article-title":"Bispecific antibodies for lymphoid Malignancy treatment","volume":"17","author":"Bisio","year":"2025","journal-title":"Cancers"},{"key":"B98","article-title":"A novel CD19\/CD22\/CD3 trispecific antibodyenhances therapeutic efficacy and overcomes immune escape against BALL Blood","volume":"140","author":"Zhao","year":"2022"},{"key":"B99","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological Malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature."},{"key":"B101","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/ejh.14076","article-title":"CAR-T cell therapy in hematological Malignancies: Where are we now and where are we heading for","volume":"112","author":"Khan","year":"2024","journal-title":"Eur J Haematology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological Malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: One size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood. Am Soc Hematology;"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the american society for transplantation and cellular therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplantation."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01680-z","article-title":"Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia","volume":"57","author":"Ohmoto","year":"2022","journal-title":"Bone Marrow Transplantation"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1473","article-title":"Analysis of glucocorticoid receptors and their apoptotic response to dexamethasone in male murine B cells during development","volume":"155","author":"Gruver-Yates","year":"2014","journal-title":"Endocrinology."},{"key":"B110","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinology."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad474","article-title":"Unintended consequences: risk of opportunistic infections associated with long-term glucocorticoid therapies in adults","volume":"78","author":"Chastain","year":"2024","journal-title":"Clin Infect Diseases."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2021.101757","article-title":"Immunosuppressive drugs modes of action","author":"Meneghini","year":"2021","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-022-04560-2","article-title":"Mycophenolate mofetil-induced hypogammaglobulinemia and infectious disease susceptibility in pediatric patients with chronic rheumatic disorders: a monocentric retrospective study","volume":"181","author":"Barbati","year":"2022","journal-title":"Eur J Pediatr"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00992-8","article-title":"Effect of DMARDs on the immunogenicity of vaccines","volume":"19","author":"van Sleen","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.12.068","article-title":"Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine","volume":"35","author":"Kapetanovic","year":"2017","journal-title":"Vaccine."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01483-x","article-title":"JAKs and STATs from a clinical perspective: loss-of-function mutations, gain-of-function mutations, and their multidimensional consequences","volume":"43","author":"Ott","year":"2023","journal-title":"J Clin Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1087986","article-title":"JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis","volume":"14","author":"Frede","year":"2023","journal-title":"Front Immunol"},{"key":"B118","unstructured":"nter for drug evaluation and research application number: 125370 labeling"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Sci (1979)."},{"key":"B120","article-title":"Effi cacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Pineda","year":"2011","journal-title":"Lancet"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111587","article-title":"Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial","volume":"39","author":"Chatham","year":"2012","journal-title":"J Rheumatol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/art.40439","article-title":"Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: A continuation of a seventy-six\u2013week phase III parent study in the United States","volume":"70","author":"Furie","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000499","article-title":"Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE","volume":"9","author":"Struemper","year":"2022","journal-title":"Lupus Sci Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152099","article-title":"Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis","volume":"57","author":"Ko","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"B125","article-title":"Depression of immune competence by phenytoin and carbamazepine studies in vivo and in vitro","volume":"20","author":"Sorrell","year":"1975","journal-title":"Clin Exp Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)90547-2","article-title":"Depression of immunological function in patients treated with phenytoin sodium (Sodium diphenylhydantoin)","volume":"298","author":"Sorrell","year":"1971","journal-title":"Lancet"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.12.013","article-title":"Carbamazepine-induced hypogammaglobulinemia","volume":"21","author":"Ozaras","year":"2012","journal-title":"Seizure."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13296","article-title":"Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies","volume":"83","author":"Zaccara","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"111104","DOI":"10.1016\/j.brainresbull.2024.111104","article-title":"The effect of clozapine on immune-related biomarkers in schizophrenia patients","volume":"218","author":"Shao","year":"2024","journal-title":"Brain Res Bull"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21197019","article-title":"A working hypothesis regarding identical pathomechanisms between clinical efficacy and adverse reaction of clozapine via the activation of connexin43","volume":"21","author":"Okada","year":"2020","journal-title":"Int J Mol Sci MDPI AG;"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2019-100183","article-title":"Clozapine is strongly associated with the risk of pneumonia and inflammation","volume":"33","author":"De Leon","year":"2020","journal-title":"Gen Psychiatry"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00447-20","article-title":"CD8 + T cell immunity is compromised by anti-CD20 treatment and rescued by interleukin-17A","volume":"11","author":"Fiocca Vernengo","year":"2020","journal-title":"mBio"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.009","article-title":"Rituximab-associated neutropenia","volume":"47","author":"Dunleavy","year":"2010","journal-title":"Semin Hematol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"106692","DOI":"10.1016\/j.msard.2025.106692","article-title":"Ocrelizumab-induced neutropenia in people with multiple sclerosis: a single-centre study","volume":"103","author":"Sartori","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton\u2019s tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood."},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"B138","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.ctrv.2022.102427","article-title":"Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review","volume":"109","author":"Blayney","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S136803","article-title":"Protein losing enteropathy: Comprehensive review of the mechanistic association with clinical and subclinical disease states","volume":"10","author":"Levitt","year":"2017","journal-title":"Clin Exp Gastroenterology."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01299-1","article-title":"Protein-losing enteropathy as a complication and\/or differential diagnosis of common variable immunodeficiency","volume":"42","author":"Sanges","year":"2022","journal-title":"J Clin Immunol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000233192.77521.2f","article-title":"Recurrent and opportunistic infections in children with primary intestinal lymphangiectasia","volume":"44","author":"Miranda Dierselhuis","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.899636","article-title":"Intestinal lymphangiectasia: Insights on management and literature review","volume":"17","author":"Alshikho","year":"2016","journal-title":"Am J Case Rep"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-023-01697-7","article-title":"Nephrotic syndrome: pathophysiology and consequences","volume":"36","author":"Claudio","year":"2023","journal-title":"J Nephrol."},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(12)80899-7","article-title":"Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome","volume":"24","author":"Ogi","year":"1994","journal-title":"Am J Kidney Diseases."},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.19082\/3728","article-title":"Immunoglobulin G and M levels in childhood nephrotic syndrome: two centers Egyptian study","volume":"9","author":"Mohamed El Mashad","year":"2017","journal-title":"Electron Physician."},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.602826","article-title":"Evaluation of immune and vaccine competence in steroid-sensitive nephrotic syndrome pediatric patients","volume":"12","author":"Colucci","year":"2021","journal-title":". Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00339","article-title":"Safety and efficacy of pneumococcal vaccination in pediatric nephrotic syndrome","volume":"7","author":"Goonewardene","year":"2019","journal-title":"Front Pediatr"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003964.pub3","article-title":"Interventions for preventing infection in nephrotic syndrome","volume":"2017","author":"Wu","year":"2012","journal-title":"Cochrane Database Systematic Rev"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00856-1","article-title":"Secondary bacterial infections in patients with atopic dermatitis or other common dermatoses","volume":"25","author":"Salle","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.04.003","article-title":"Immune dysfunction as a cause and consequence of malnutrition","volume":"37","author":"Bourke","year":"2016","journal-title":"Trends Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3390\/nu17091469","article-title":"Macronutrients, micronutrients, and malnutrition: effects of nutrition on immune function in infants and young children","volume":"17","author":"van Neerven","year":"2025","journal-title":"Nutrients"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.830294","article-title":"Dietary intake and pneumococcal vaccine response among children (5\u20137 years) in msambweni division, kwale county, Kenya","volume":"9","author":"Migliore","year":"2022","journal-title":"Front Nutr"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/nri2524","article-title":"B cells in HIV infection and disease","volume":"9","author":"Moir","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B157","doi-asserted-by":"crossref","unstructured":"Longwe\n              H\n            \n            \n              Gordon\n              S\n            \n            \n              Malamba\n              R\n            \n            \n              French\n              N\n            \n          \n          Characterising B cell numbers and memory B cells in HIV infected and uninfected Malawian adults\n          \n          2010","DOI":"10.1186\/1471-2334-10-280"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit937","article-title":"Long-term immune responses to vaccination in HIV-infected patients: A systematic review and meta-analysis","volume":"58","author":"Kerneis","year":"2014","journal-title":"Clin Infect Diseases."},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.3.631","article-title":"Hypogammaglobulinemia associated with cytomegalovirus pneumonia","volume":"163","author":"Greenberger","year":"1991","journal-title":"J Infect Diseases."},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOCI.0000040922.26286.36","article-title":"Persistent hypogammaglobulinemia following mononucleosis in boys is highly suggestive of X-linked lymphoproliferative disease\u2014Report of three cases","volume":"24","author":"H\u00fcgle","year":"2004","journal-title":"J Clin Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.068791","article-title":"Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27","volume":"98","author":"Salzer","year":"2013","journal-title":"Haematologica."},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.4.437-443.2006","article-title":"Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals","volume":"13","author":"Permar","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jaci.2021.04.015","article-title":"Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations","volume":"148","author":"Thalhammer","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2017.03.011","article-title":"Delay in diagnosis affects the clinical outcome in a cohort of cvid patients with marked reduction of iga serum levels","volume":"180","author":"Graziano","year":"2017","journal-title":"Clin Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00694","article-title":"Delayed diagnosis and complications of predominantly antibody deficiencies in a cohort of Australian adults","volume":"9","author":"Slade","year":"2018","journal-title":"Front Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928062","article-title":"Secondary immune deficiency and primary immune deficiency crossovers: hematological Malignancies and autoimmune diseases","volume":"13","author":"Ballow","year":"2022","journal-title":"Front Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149667","article-title":"Secondary rituximab-associated versus primary immunodeficiencies: The enigmatic border","volume":"52","author":"Ottaviano","year":"2022","journal-title":"Eur J Immunol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: Antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B169","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13052-021-01150-0","article-title":"Italian Journal of Pediatrics. BioMed Central Ltd","volume":"47","author":"Chiappini","year":"2021","journal-title":"Ital J Pediatr"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13451","article-title":"Paediatric and adult bronchiectasis: Monitoring, cross-infection, role of multidisciplinary teams and self-management plans","volume":"24","author":"Navaratnam","year":"2019","journal-title":"Respirology. Blackwell Publishing;"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00093-0","article-title":"Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)","volume":"11","author":"Chalmers","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B173","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1513\/AnnalsATS.201310-335OC","article-title":"A novel microbiota stratification system predicts future exacerbations in bronchiectasis","volume":"11","author":"Rogers","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"B174","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1038\/s41598-017-04495-x","article-title":"Infection is an independent predictor of death in diffuse large B cell lymphoma","volume":"7","author":"Dendle","year":"2017","journal-title":"Sci Rep"},{"key":"B175","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-022-00652-2","article-title":"A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma","volume":"12","author":"Encinas","year":"2022","journal-title":"Blood Cancer J"},{"key":"B176","article-title":"The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"Mankarious","year":"1988","journal-title":"J Lab Clin Med"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01541","article-title":"he natural history of untreated primary hypogammaglobulinemia in adults: implications for the diagnosis and treatment of common variable immunodeficiency disorders (CVID)","volume":"10","author":"Ameratunga","year":"2019","journal-title":"Front Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin Chem"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00319","article-title":"Serum free light chains in common variable immunodeficiency disorders: role in differential diagnosis and association with clinical phenotype","volume":"11","author":"Scarpa","year":"2020","journal-title":"Front Immunol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia."},{"key":"B181","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","article-title":"International consensus document (ICON): common variable immunodeficiency disorders","volume":"4","author":"Bonilla","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.02.004","article-title":"The european society for immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity","volume":"7","author":"Seidel","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12178","article-title":"New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin","volume":"174","author":"Ameratunga","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.05.028","article-title":"Specific antibody deficiency: pearls and pitfalls for diagnosis","volume":"129","author":"Lawrence","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.08.012","article-title":"Antibody deficiency testing for primary immunodeficiency","volume":"123","author":"Marsh","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"266:110320","DOI":"10.1016\/j.clim.2024.110320","article-title":"Limitations in the clinical utility of vaccine challenge responses in the evaluation of primary antibody deficiency including Common Variable Immunodeficiency Disorders","author":"Ameratunga","year":"2024","journal-title":"Clin Immunol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.3390\/cells10112915","article-title":"B cell response induced by SARS-coV-2 infection is boosted by the BNT162b2 vaccine in primary antibody deficiencies","volume":"10","author":"Pulvirenti","year":"2021","journal-title":"Cells."},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01133-0","article-title":"SARS-coV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best","volume":"41","author":"Salinas","year":"2021","journal-title":"J Clin Immunol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01231-7","article-title":"SARS-coV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study","volume":"42","author":"Shields","year":"2022","journal-title":"J Clin Immunol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.12.980","article-title":"Update: Vaccines in primary immunodeficiency","volume":"141","author":"Bonilla","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-013-9977-z","article-title":"Measurement of pneumococcal polysaccharide antibodies","volume":"34","author":"Sorensen","year":"2014","journal-title":"J Clin Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.24507","article-title":"Comprehensive phenotyping of human peripheral blood B lymphocytes in healthy conditions","volume":"101","author":"Carsetti","year":"2022","journal-title":"Cytometry Part A."},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.226","article-title":"Human memory B cells","volume":"30","author":"Seifert","year":"2016","journal-title":"Leukemia."},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1038\/nri3804","article-title":"Dynamics of B cells in germinal centres","volume":"15","author":"De Silva","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22222","article-title":"Longitudinal monitoring of class-switched memory-B cell proportions identifies plausible germinal center failure in patients with suspected immune disorders","volume":"10","author":"Knight","year":"2025","journal-title":"Cytometry B Clin Cytom"},{"key":"B196","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature","volume":"2","author":"Kaplan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690328","article-title":"B-cell immunophenotyping to predict vaccination outcome in the immunocompromised - A systematic review","volume":"12","author":"Diks","year":"2021","journal-title":"Front Immunol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.736","article-title":"Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation","volume":"4","author":"Silbermann","year":"2023","journal-title":"EJHaem."},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jaci.2019.01.051","article-title":"Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies","volume":"144","author":"Milito","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"240183","DOI":"10.1183\/16000617.0183-2024","article-title":"Risk factors for drug-resistant pathogens in community-acquired pneumonia: systematic review and meta-analysis","volume":"34","author":"Nakagawa","year":"2025","journal-title":"Eur Respir Review."},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011231","article-title":"Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological Malignancy","volume":"8","author":"McQuilten","year":"2024","journal-title":"Blood Adv"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.2217\/IMT.15.74","article-title":"Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities","volume":"7","author":"Eibl","year":"2015","journal-title":"Vol. 7 Immunother"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.01.061","article-title":"Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET)","volume":"36","author":"Martire","year":"2018","journal-title":"Vaccine."},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9639-y","article-title":"Dendritic and T cell response to influenza is normal in the patients with X-linked agammaglobulinemia","volume":"32","author":"Liu","year":"2012","journal-title":"J Clin Immunol"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3390\/v15081659","article-title":"BNT162b2 elicited an efficient cell-mediated response against SARS-coV-2 in kidney transplant recipients and common variable immunodeficiency patients","volume":"15","author":"La Civita","year":"2023","journal-title":"Viruses."},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00522","article-title":"Bronchiectasis in primary antibody deficiencies: A multidisciplinary approach","volume":"11","author":"Wall","year":"2020","journal-title":"Front Immunol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"key":"B210","unstructured":"Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and\/or intramuscular administration (SCIg\/IMIg) rev 2\n          \n          2024"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.12.004","article-title":"Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches","volume":"23","author":"Morrison","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"B212","unstructured":"Antimicrobial resistance in the EU\/EEA (EARS-Net) EU targets on antimicrobial resistance"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220626","article-title":"Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression","volume":"80","author":"Prendecki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1038\/nature24633","article-title":"Origin and differentiation of human memory CD8 T cells after vaccination","volume":"552","author":"Akondy","year":"2017","journal-title":"Nature."},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-024-01903-7","article-title":"Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans","volume":"10","author":"Kalimuddin","year":"2025","journal-title":"Nat Microbiol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl5344","article-title":"BNT162b2 vaccination induces durable SARS-CoV-2\u2013specific T cells with a stem cell memory phenotype","volume":"6","author":"Guerrera","year":"2021","journal-title":"Sci Immunol"},{"key":"B217","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/biom6010015","article-title":"The production processes and biological effects of intravenous immunoglobulin","volume":"6","author":"Barahona Afonso","year":"2016","journal-title":"Biomolecules."},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13665","article-title":"Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study","volume":"206","author":"Martinez","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02412.x","article-title":"Increased risk of adverse events when changing intravenous immunoglobulin preparations","volume":"136","author":"Ameratunga","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"B221","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B222","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1016\/j.jaip.2023.05.005","article-title":"Detection of SARS-coV-2 antibodies in immunoglobulin products","volume":"11","author":"Cousins","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1452106","article-title":"Contribution of immunoglobulin products in influencing seasonal influenza infection and severity in antibody immune deficiency patients receiving immunoglobulin replacement therapy","volume":"15","author":"Ballow","year":"2024","journal-title":"Front Immunol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013073","article-title":"IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence","volume":"8","author":"Soumerai","year":"2024","journal-title":"Blood Adv"},{"key":"B225","article-title":"Subcutaneous gammaglobulin for patients with secondary hypogammaglobulinaemia","volume":"345","author":"Hammarstr\u00f6m","year":"1995","journal-title":"Lancet."},{"key":"B226","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V73.2.366.366","article-title":"Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors","volume":"73","author":"Griffiths","year":"1989","journal-title":"Blood."},{"key":"B227","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2147\/COPD.S236656","article-title":"Hypogammaglobulinemia and risk of exacerbation and mortality in patients with COPD","volume":"15","author":"Holm","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B228","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/bmb\/ldn034","article-title":"The immunodeficiency of chronic lymphocytic leukaemia","volume":"87","author":"Hamblin","year":"2008","journal-title":"Br Med Bull"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.12.024","article-title":"If and when to consider prophylactic immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"13","author":"Otani","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2022.113350","article-title":"Application of vaccine response in the evaluation of patients with suspected B-cell immunodeficiency: Assessment of responses and challenges with interpretation","volume":"510","author":"Peterson","year":"2022","journal-title":"J Immunol Methods"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211035272","article-title":"Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study","volume":"12","author":"Vitkon","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients A B C","volume":"105","author":"Frerichs","year":"2020","journal-title":"Haematologica"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010022","article-title":"A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody deficiency","volume":"30","author":"Visentin","year":"2023","journal-title":"Curr Oncol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.04.001","article-title":"Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia","author":"Spadaro","year":"2016","journal-title":"Clin Immunol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13223-024-00939-y","article-title":"Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction","volume":"21","author":"Mallick","year":"2025","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12760","article-title":"Cost\u2013utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency","volume":"114","author":"Windegger","year":"2019","journal-title":"Vox Sang."},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol Allergy Clinics North America."},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000864","article-title":"Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding","volume":"22","author":"Morgan","year":"2022","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B239","article-title":"Efficacy of subcutaneous immunoglobulins in primary immunodeficiency with Crohn\u2019 s-like phenotype: report of a case","volume-title":"Eur Rev Med Pharmacol Sci","author":"Sanges","year":"2015"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12485","article-title":"Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease","volume":"179","author":"Jolles","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B241","unstructured":"Committee for Medicinal Products for Human Use (CHMP) Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg)\n          \n          2021"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247717","article-title":"Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies","volume":"16","author":"Cinetto","year":"2021","journal-title":"PloS One"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18212","article-title":"Multiple myeloma treatment \u2013 should be continued or not","volume":"198","author":"Ozaki","year":"2022","journal-title":"Br J Haematology"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00782","article-title":"B cell reconstitution and influencing factors after hematopoietic stem cell transplantation in children","volume":"10","author":"Van Der Maas","year":"2019","journal-title":"Front Immunol"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.06.035","article-title":"Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab\u2014for how long","volume":"136","author":"Barmettler","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900","article-title":"Immunoglobulin replacement therapy discontinuation in patients with antibody deficiency secondary to hematological Malignancy","volume":"39","author":"Patel","year":"2021","journal-title":"Hematological Oncol"},{"key":"B248","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3747\/co.23.2810","article-title":"A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia","volume":"23","author":"Lachance","year":"2016","journal-title":"Curr Oncol Multimed Inc.;"},{"key":"B249","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12308-020-00415-7","article-title":"Low class-switched memory B cells predict the need for continued immunoglobulin replacement following B cell reconstitution after rituximab: a case series and review of the literature","volume":"13","author":"Mcnulty","year":"2020","journal-title":"J Hematopathol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672413\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:33:33Z","timestamp":1764830013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672413\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":249,"alternative-id":["10.3389\/fimmu.2025.1672413"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1672413","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"article-number":"1672413"}}